FBT is a popular choice among biotech funds, managing to accumulate substantial assets despite taking a somewhat unusual approach to the segment. The underlying index contains only 30 names (increased from 20 in October 2014), which is more limited than some other funds in the segment, such as IBB and XBI. Exposure includes access to pharmaceuticals and medical technology in addition to traditional biotech, with a higher small-cap and midcap presence than our segment benchmark. The bias away from larger firms stems from the equally weighted basket, an approach thatβs not unusual. Still, FBTβs equal weighting of about 30 stocks produces a relatively concentrated basket. FBT trades well with reasonably tight spreads and remains a formidable name in the biotechnology sector.
All Holdings from FBT
ACADIA Pharmaceuticals Inc. | 4.02% |
---|---|
Ionis Pharmaceuticals, Inc. | 3.91% |
Ultragenyx Pharmaceutical, Inc. | 3.84% |
bluebird bio, Inc. | 3.82% |
Charles River Laboratories International, Inc. | 3.81% |
Bio-Techne Corporation | 3.79% |
Agios Pharmaceuticals, Inc. | 3.71% |
Alexion Pharmaceuticals, Inc. | 3.69% |
IQVIA Holdings Inc | 3.52% |
Incyte Corporation | 3.51% |
FibroGen, Inc. | 3.50% |
United Therapeutics Corporation | 3.49% |
QIAGEN NV | 3.32% |
Regeneron Pharmaceuticals, Inc. | 3.28% |
Alnylam Pharmaceuticals, Inc | 3.27% |
Seattle Genetics, Inc. | 3.22% |
Illumina, Inc. | 3.20% |
Grifols, S.A. Sponsored ADR Class B | 3.18% |
Exelixis, Inc. | 3.16% |
Alkermes Plc | 3.11% |
Biogen Inc. | 3.10% |
Vertex Pharmaceuticals Incorporated | 3.09% |
Celgene Corporation | 3.08% |
BioMarin Pharmaceutical Inc. | 3.05% |
Gilead Sciences, Inc. | 3.00% |
Amgen Inc. | 2.98% |
Intrexon Corporation | 2.88% |
Intercept Pharmaceuticals, Inc. | 2.81% |
Nektar Therapeutics | 2.80% |
Neurocrine Biosciences, Inc. | 2.70% |